Scientists Warn Popular Anti-Aging Drug Combo May Damage The Brain

A drug combination promoted in longevity circles as a potential anti-aging therapy may carry serious neurological risks, according to new preclinical research. Scientists report that dasatinib plus quercetin, a senolytic cocktail known as D+Q, caused extensive brain damage in mice, particularly in younger animals.

The study, led by researchers at the University of Connecticut School of Medicine and published in PNAS, found that D+Q severely disrupted myelin, the fatty sheath that insulates nerve fibers. Myelin is essential for rapid and coordinated communication between brain regions and throughout the nervous system.

Dasatinib is a chemotherapy drug approved for certain forms of leukemia, while quercetin is a plant-derived flavonoid widely sold as a dietary supplement. Together, they form one of the best-known senolytic regimens, designed to remove aged and damaged cells linked to chronic inflammation and age-related disease.

D+Q has already been tested in small human studies for conditions such as idiopathic pulmonary fibrosis, diabetic kidney disease, and frailty. It is also being investigated in early-stage Alzheimer’s disease trials. At the same time, some longevity enthusiasts have experimented with off-label or self-directed use despite the lack of long-term safety data.

Until now, most research focused on possible benefits in aging tissues such as fat, bone, and the cardiovascular system. The new findings suggest that the brain, particularly myelin-producing cells, may be especially vulnerable to this drug combination.

Severe Myelin Loss In Treated Mice

To investigate neurological effects, researchers treated young adult mice aged 6 to 9 months and older mice around 22 months with D+Q. They also exposed oligodendrocytes, the specialized cells responsible for producing and maintaining myelin, to the drug combination in laboratory cultures.

Microscopic analysis revealed that healthy control animals had thick and intact myelin sheaths surrounding nerve fibers. In contrast, mice treated with D+Q showed dramatically thinned or missing myelin, indicating widespread damage across several important brain regions.

The damage was especially severe in the corpus callosum, the major structure connecting the brain’s two hemispheres. Injury to this region has been associated with slowed thinking, coordination problems, and cognitive symptoms similar to the so-called “chemo brain” experienced by some cancer patients.

Cells Regress Instead Of Dying

Unexpectedly, researchers did not observe large-scale death of oligodendrocytes. Instead, the cells appeared to regress into a more immature state, losing their complex branching structures and behaving more like juvenile precursor cells than fully functional myelin-producing cells.

Metabolic analyses suggested that D+Q disrupted the cells’ energy pathways, depriving them of the fuel needed to maintain their highly specialized architecture. As a result, the oligodendrocytes shifted into a simpler and less energy-demanding developmental state.

These altered cells closely resembled a unique oligodendrocyte population previously identified in patients with multiple sclerosis. This similarity suggests that stressed myelin-producing cells in multiple sclerosis may not simply die, but instead become trapped in a dysfunctional immature-like state.

Implications For Multiple Sclerosis Research

Multiple sclerosis is characterized by immune-driven attacks on myelin, leading to symptoms such as numbness, weakness, visual disturbances, and cognitive problems. Traditional theories have focused primarily on oligodendrocyte loss, but the new findings suggest some of these cells may survive in a compromised condition.

If such stressed cells retain the ability to recover, they could potentially become targets for future therapies aimed at reactivating or reprogramming them to restore myelin production. The D+Q-induced model may provide researchers with a controlled way to study how these dysfunctional cells develop and whether they can be rescued.

Scientists are now investigating whether damaged oligodendrocytes in this mouse model can recover and whether improving metabolic support may help restore myelin formation. Such findings could eventually contribute to new remyelination strategies for multiple sclerosis and related neurological disorders.

Warning For Off-Label Longevity Use

The authors and other experts caution that these findings, although limited to mice and cell cultures, raise concerns for individuals using senolytic therapies outside controlled clinical trials. Younger animals in the study experienced more severe myelin disruption than older ones, suggesting that youth does not provide protection against potential neurological harm.

Myelin damage in humans can lead to long-lasting neurological and cognitive complications, and the brain’s ability to repair such injury decreases with age. Because there is currently no established safe dose, treatment schedule, or long-term safety profile for D+Q in healthy individuals, neurologists warn that self-experimentation may involve significant hidden risks.

Regulators and clinicians continue to emphasize that senolytics remain an experimental class of drugs. The new findings strengthen calls for carefully controlled trials, detailed neurocognitive monitoring, and extensive preclinical safety testing before D+Q can be more broadly considered in the context of healthy aging.

As anti-aging research accelerates, the study highlights a broader lesson: interventions that appear beneficial for some tissues may also produce unintended and organ-specific harms elsewhere, especially in the brain. Long-term safety must be demonstrated rather than assumed before such therapies move beyond experimental settings.